MX2022000052A - Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766. - Google Patents

Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766.

Info

Publication number
MX2022000052A
MX2022000052A MX2022000052A MX2022000052A MX2022000052A MX 2022000052 A MX2022000052 A MX 2022000052A MX 2022000052 A MX2022000052 A MX 2022000052A MX 2022000052 A MX2022000052 A MX 2022000052A MX 2022000052 A MX2022000052 A MX 2022000052A
Authority
MX
Mexico
Prior art keywords
enhancing therapeutic
cancer compound
therapeutic compliance
cancer
compliance
Prior art date
Application number
MX2022000052A
Other languages
English (en)
Inventor
Rongrong Jiang
Vaishali Dixit
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2022000052A publication Critical patent/MX2022000052A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se reportan sistemas para reducir el error de medicación y aumentar el cumplimiento terapéutico de un individuo que padece cáncer. Las modalidades proporcionan información sobre la interacción farmacológica para la dosificación del Compuesto 1 terapéutico antineoplásico (E7766) en posible combinación con un inhibidor de OATP.
MX2022000052A 2019-07-01 2020-07-01 Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766. MX2022000052A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962869389P 2019-07-01 2019-07-01
PCT/US2020/040515 WO2021003279A1 (en) 2019-07-01 2020-07-01 System for enhancing therapeutic compliance of the anti-cancer compound e7766

Publications (1)

Publication Number Publication Date
MX2022000052A true MX2022000052A (es) 2022-04-06

Family

ID=71895194

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000052A MX2022000052A (es) 2019-07-01 2020-07-01 Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766.

Country Status (10)

Country Link
US (1) US20220304982A1 (es)
EP (1) EP3993809A1 (es)
JP (1) JP2022538898A (es)
KR (1) KR20220029717A (es)
CN (1) CN114599374A (es)
AU (1) AU2020300543A1 (es)
BR (1) BR112021026876A2 (es)
CA (1) CA3145824A1 (es)
MX (1) MX2022000052A (es)
WO (1) WO2021003279A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023039363A1 (en) 2021-09-09 2023-03-16 Eisai R&D Management Co., Ltd. Biomarkers for sting agonists and methods of using the same
CN115512788B (zh) * 2022-09-16 2023-08-08 山东大学 预测SGLTi人体暴露量及靶蛋白抑制率的方法及系统

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2446893A1 (en) * 2010-11-01 2012-05-02 Bergen Teknologioverføring AS Use of nontoxic cyclic peptides to block transport via OATP1B1/ OATP1B3-related proteins, for the treatment of cancer cells expressing such transporters
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer

Also Published As

Publication number Publication date
CA3145824A1 (en) 2021-01-07
EP3993809A1 (en) 2022-05-11
US20220304982A1 (en) 2022-09-29
CN114599374A (zh) 2022-06-07
BR112021026876A2 (pt) 2022-02-22
KR20220029717A (ko) 2022-03-08
WO2021003279A1 (en) 2021-01-07
AU2020300543A1 (en) 2022-02-24
JP2022538898A (ja) 2022-09-06

Similar Documents

Publication Publication Date Title
MX2022000052A (es) Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766.
Calzavara‐Pinton et al. Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque‐type psoriasis
PH12019502545A1 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
Bajwa et al. Anesthesia and cancer recurrences: The current knowledge and evidence
NO20044261L (no) Indazoler substituerte med en anticanceros aktivitet
NZ730560A (en) Control system for control of distribution of medication
WO2006082428A3 (en) Combination therapies using hdac inhibitors
EA201200560A1 (ru) Специфическая терапия, использующая интегриновые лиганды для лечения рака
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
Hughes et al. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
TN2010000204A1 (en) Kinesin inhibitors as cancer therapeutics
EA200900912A1 (ru) Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
Dugas‐Breit et al. New and established treatment options for mycosis fungoides and Sézary syndrome–an update
Punt et al. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity
MX2022003648A (es) Sistema de administración de fármaco configurado para determinar un esquema de dosificación de fármaco.
Haustrate et al. RETRACTED: TRPV6 calcium channel regulation, downstream pathways, and therapeutic targeting in cancer
BR112021016923A2 (pt) Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
DK1611252T3 (da) In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren
BR112023026076A2 (pt) Terapia combinada de radioimunoconjugados e inibidores de checkpoint
MX2019014330A (es) Paradigma de tratamiento para un tratamiento de combinacion de anticuerpo anti-cd19 y venetoclax.
Ribrag et al. Safety and efficacy of abexinostat, a pan-histone deacetylase (HDAC) inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of an ongoing phase 2 study
MX2022011711A (es) Compuesto de oxofenilarsina deuterada y uso del mismo.
Ippolito et al. Omipalisib (GSK458), a novel Pan-PI3K/mTOR inhibitor, exhibits in vitro anti-lymphoma activity in chemotherapy-sensitive and-resistant models of burkitt lymphoma